Abiomed, founded in 1981 originally as Applied Biomedical Corporation, designs, develops and manufactures medical implant devices, such as pacemakers and artificial hearts.
The company created the first artificial heart in 2001. Since then, the Impella heart device has received numerous FDA approvals for its use. In addition to the heart pump, the company engages in the research, development, prototyping, and the pre-serial production of a percutaneous expandable catheter pump, which enhances blood circulation from the heart. Abiomed went public on the NYSE and can be found under the ticker symbol: ABMD.
In 2016, the company reported $329.5 million in revenue, $65.1 million in operating income, $38.1 million in net income, $423 million in total assets, and $369 million in equity. Abiomed operates in the US, Canada, Europe, and Japan.